Immunogenicity Testing: Eliminating Target Interference

Cover Articles
July 11, 2022
by Cathy Yarborough, Science Writer

The Covid pandemic’s disruption of the global supply chain has limited the availability of human plasma and other biological matrices for studies on evaluating the immunogenicity of therapeutic proteins and peptides, said Jennifer Zemo, Ph.D., speaker in the virtual AAPS workshop, “Measurement and Understanding of Immune Response in Context of Clinical Development.”